Retrospective Evaluation of the Analgesic Effects of Molecular Target Agents Against Cancer Pain and Oxaliplatin-Induced Chronic Peripheral Neuropathy

• Shu Yuasa

  Department of Hospital Pharmacy, Nagoya Memorial Hospital, Japan

• Megumi Kabeya

  Department of Hospital Pharmacy, Nagoya Memorial Hospital, Japan and Palliative Care Team, Nagoya Memorial Hospital, Japan

• Satoshi Hibi

  Department of Hospital Pharmacy, Nagoya Memorial Hospital, Japan

• Yuko Shirokawa

  Department of Nursing, Nagoya Memorial Hospital, Japan

• Chiaki Tokoro

  Department of Nursing, Nagoya Memorial Hospital, Japan and Palliative Care Team, Nagoya Memorial Hospital, Japan

• Ryuichi Furuta

  Department of Clinical Oncology, Nagoya Memorial Hospital, Japan

• Seiji Nagao

  Palliative Care Team, Nagoya Memorial Hospital, Japan

• Satoshi Kayukawa

  Department of Clinical Oncology, Nagoya Memorial Hospital, Japan

• Yoshiteru Tanaka

  Shinseikai Dai-ichi Hospital, Nagoya, Japan

• Kenji Ina

  Shinseikai Dai-ichi Hospital, Nagoya, Japan

Epidermal growth factor receptor (EGFR) has received significant attention for its therapeutic potential for pain relief. The relief of neuropathic pain after treatment with anti-EGFR antibodies or tyrosine kinase inhibitors has been previously described. However, few reports have investigated the association of cancer-related nociceptive pain or chronic chemical induced peripheral neuropathy with the analgesic effects of EGFR inhibition.

Therefore, we conducted a retrospective survey of 191 patients with colorectal cancer receiving chemotherapy plus molecular targeting drugs to examine the analgesic effects of anti-EGFR antibodies against either cancer pain or oxaliplatin-induced peripheral neuropathy. We identified a significant difference in the improvement rates of nociceptive pain between panitumumab- and bevacizumab-treated patients (100% vs. 9.1%; p < 0.01), but not oxaliplatin-induced peripheral neuropathy.

In conclusion, panitumumab may be effective at reducing cancer-related nociceptive pain.

Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-10. https://doi.org/10.1038/35093019

Martin LJ, Smith SB, Khoutorsky A, et al. Epiregulin and EGFR interactions are involved in pain processing. J Clin Invest 2017; 127: 3353-66. https://doi.org/10.1172/JCI87406

Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol 2013; 8: 229-37. https://doi.org/10.1097/JTO.0b013e3182773fce

Kersten C, Cameron MG, Laird B, Mjaland S. Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain. Br J Anaesthesia 2015; 115: 761-767. https://doi.org/10.1093/bja/aev326

Kersten C, Cameron MG, Bailey AG, et al. Relief of neuropathic pain through epidermal growth factor receptor inhibition: A randomized proof-of-concept trial. Pain Med 2019; 20: 2495-2505. https://doi.org/10.1093/pm/pnz101

Kersten C, Cameronb MG. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Reports 2012. pii: bcr1220115374. https://doi.org/10.1136/bcr.12.2011.5374

Yuasa S, Kabeya M, Furuta R, et al. Case of sigmoid colon cancer in which somatic pain was rapidly alleviated after panitumumab administration despite tumor progression. J Anal Oncol 2016; 5: 38-41. https://doi.org/10.6000/1927-7229.2016.05.01.5

Borges JP, Mekhail K, Fairn GD, Antonescu CN, Steinberg BE. Modulation of pathological pain by epidermal growth factor receptor. Front Pharmacol 2021; 12: 642820. https://doi.org/10.3389/fphar.2021.642820

Zhuang ZY, Gerner P, Woolf C, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005; 114: 149-59. https://doi.org/10.1016/j.pain.2004.12.022

Douillard JY, Siena S, Cassidy J, et al. Randomized phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2010; 28: 4697-705. https://doi.org/10.1200/JCO.2009.27.4860

Kang L, Tian Y, Xu S, Chen H. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment. J Neurol 2021; 268: 3269-82. https://doi.org/10.1007/s00415-020-09942-w

Japanese society for palliative medicine. Clinical guideline for cancer pain management third edition, Kanehara & Co. Ltd, Tokyo Japan 2020; pp. 22-26.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplantation 2013; 48: 452-458. https://doi.org/10.1038/bmt.2012.244

Puig S, Donica CL, Gustein HB. EGFR signaling causes morphine tolerance and mechanical sensitization in rats. eNeuro 2020; 7: 1-12. https://doi.org/10.1523/ENEURO.0460-18.2020

Verma V, Khoury S, Parisien M, et al. The dichomatous role of epiregulin in pain. Pain 2020; 161: 1052-64. https://doi.org/10.1097/j.pain.0000000000001792

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.